The executives of pharmaceutical companies are usually known for their high incomes.
If bonuses and stock options are also taken into account, the annual salary of the CEOs of pharmaceutical giants can generally reach tens of millions of dollars, such as Pfizer's Albert Bourla and Johnson & Johnson's Alex Gorsky and Pascal Soriot of AstraZeneca.
In the past few weeks, life sciences and biopharmaceutical companies have successively announced year-end financial reports, including the total compensation of the CEO and other members of the executive team in 2020.
Among them, the annual salary of CEOs of companies involved in the development of COVID-19 vaccines has increased.
[Related reading: The salary of the CEO of the new crown vaccine manufacturer has soared! Pfizer, BioNTech, Johnson & Johnson.
According to the data released by the top 20 biopharmaceutical companies by market capitalization, the latest basic salary information of the CEOs of each company is collected and compiled.
The salary range is very large, from the lowest Vertex CEO David DeStefano's $591,710 to the highest Swiss pharmaceutical giant Roche CEO Severin Schwan's $3,785,000.
Most of the increase in the amount is in the form of bonuses and stock options.
For example, Ugur Sahin, CEO of BioNTech in Germany, received US$7.
4 million through stock options.
In addition to the basic salary, it is worth paying attention to the changes in this year's salary compared with the previous year's basic salary.
The salary of some CEOs this year only increased by a few percentage points year-on-year.
However, the basic salary of Novartis CEO Vas Narasimhan and Gilead CEO Daniel O'Day increased significantly by 29.
8% and 34.
This may be due to Remdesivir.
Caused by the early success of the COVID-19 pandemic.
In addition, the basic salary of two CEOs has fallen.
Roche Schwan’s basic salary was the highest, a decrease of 12.
5% from 2019.
Illumina CEO Francis deSouza’s basic salary dropped by 2.
If shareholder approval is obtained later this month, Johnson & Johnson CEO Alex Gorsky’s total compensation will be increased to $30 million.
However, opposition voices within the company believe that Gorsky should be responsible for litigation related to the opioid business and does not support a salary increase under the condition of causing billions of dollars in losses to the company.
Although Teva, the Israeli-based generic drug giant, is not on the list of the top 20 pharmaceutical companies by market capitalization, its CEO, Kåre Schultz, is expected to significantly increase its annual salary.
Although the base salary of US$2 million is the same as in 2019, Schultz’s stock holdings will increase by US$4 million, an increase of as much as 35%.
The following is based on the data released by the top 20 biopharmaceutical companies ranked by market capitalization, the basic salary table of CEOs prepared:
Reference source: CEO Salaries for the Top 20 Pharma Companies by Market Cap